{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:19:43Z","timestamp":1791206383147,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2005,8,22]],"date-time":"2005-08-22T00:00:00Z","timestamp":1124668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2005,8,22]],"date-time":"2005-08-22T00:00:00Z","timestamp":1124668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2005,11,1]]},"DOI":"10.1038\/sj.bmt.1705138","type":"journal-article","created":{"date-parts":[[2005,8,22]],"date-time":"2005-08-22T04:59:12Z","timestamp":1124686752000},"page":"771-779","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140\u2009mg\/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects"],"prefix":"10.1038","volume":"36","author":[{"given":"J-F","family":"Rossi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Fegueux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z Y","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Legouffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Exbrayat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M-C","family":"Bozonnat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Quittet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J-P","family":"Daures","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Rouill\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Kanouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Widjenes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,8,22]]},"reference":[{"key":"BF1705138_CR1","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJM199706053362307","volume":"336","author":"R Bataille","year":"1997","unstructured":"Bataille R, Harousseau JL . Multiple myeloma. N Engl J Med 1997; 336: 1657\u20131664.","journal-title":"N Engl J Med"},{"key":"BF1705138_CR2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M Attal","year":"1996","unstructured":"Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91\u201397.","journal-title":"N Engl J Med"},{"key":"BF1705138_CR3","first-page":"7","volume":"95","author":"S Lenhoff","year":"2000","unstructured":"Lenhoff S, Hjorth M, Holmberg E et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood 2000; 95: 7\u201311.","journal-title":"Blood"},{"key":"BF1705138_CR4","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa032290","volume":"349","author":"M Attal","year":"2003","unstructured":"Attal M, Harousseau JL, Facon T et al. InterGroupe Francophone du Myelome. single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495\u20132502.","journal-title":"N Engl J Med"},{"key":"BF1705138_CR5","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1182\/blood.V99.3.731","volume":"99","author":"P Moreau","year":"2002","unstructured":"Moreau P, Facon T, Attal M et al. Comparison of 200\u2009mg\/m2 melphalan and 8\u2009Gy total body irradiation plus 140\u2009mg\/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma final: analysis of the Intergroupe Francophone du My\u00e9lome 9502 randomized trial. Blood 2002; 99: 731\u2013735.","journal-title":"Blood"},{"key":"BF1705138_CR6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood.V93.1.51","volume":"93","author":"DS Sieghel","year":"1999","unstructured":"Sieghel DS, Desikan KR, Mehta J et al. Age is not a prognostic variable with autologous transplantation for multiple myeloma. Blood 1999; 93: 51\u201354.","journal-title":"Blood"},{"key":"BF1705138_CR7","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V89.3.789","volume":"89","author":"B Barlogie","year":"1997","unstructured":"Barlogie B, Jagannath S, Vesole DH et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789\u2013793.","journal-title":"Blood"},{"key":"BF1705138_CR8","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood.V93.1.55","volume":"93","author":"B Barlogie","year":"1999","unstructured":"Barlogie B, Jagannath S, Desikan KR et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55\u201365.","journal-title":"Blood"},{"issue":"Suppl 2","key":"BF1705138_CR9","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1038\/sj.bmt.1702348","volume":"25","author":"H Goldschmidt","year":"2000","unstructured":"Goldschmidt H, Egerer G, Ho AD . Autologous and allogenic stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2000; 25 (Suppl 2): S25\u2013S26.","journal-title":"Bone Marrow Transplant"},{"issue":"Suppt1","key":"BF1705138_CR10","first-page":"132a","volume":"88","author":"JF Rossi","year":"1996","unstructured":"Rossi JF, Legouffe E, Fegueux N et al. Autologous transplantation (AT) of CD34+ peripheral blood progenitor cells (PBPC) after double (D) high dose chemotherapy (HDC) in multiple myeloma (MM) is followed by severe immunodeficiency (ID) and high production of interleukin-6 (IL-6) related-C Reactive Protein (CRP) requiring additive immunotherapy (IT). Blood 1996; 88 (Suppt1): 132a (abstract 516).","journal-title":"Blood"},{"key":"BF1705138_CR11","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1182\/blood.V95.7.2234","volume":"95","author":"RM Lemoli","year":"2000","unstructured":"Lemoli RM, Martinelli G, Zamagni E et al. Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. Blood 2000; 95: 2234\u20132239.","journal-title":"Blood"},{"key":"BF1705138_CR12","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.1200\/JCO.2001.19.17.3771","volume":"19","author":"AK Stewart","year":"2001","unstructured":"Stewart AK, Vescio R, Schiller G et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol 2001; 19: 3771\u20133779.","journal-title":"J Clin Oncol"},{"key":"BF1705138_CR13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/332083a0","volume":"332","author":"M Kawano","year":"1988","unstructured":"Kawano M, Hirano T, Matsuda T et al. Autocrine generation and essential requirement of BSF-2\/IL-6 for human multiple myeloma. Nature 1988; 332: 83\u201387.","journal-title":"Nature"},{"key":"BF1705138_CR14","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V85.4.863.bloodjournal854863","volume":"85","author":"B Klein","year":"1995","unstructured":"Klein B, Zhang XG, Lu ZY, Bataille R . Interleukin-6 in multiple myeloma. Blood 1995; 85: 863\u2013872.","journal-title":"Blood"},{"key":"BF1705138_CR15","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1182\/blood.V73.2.517.517","volume":"73","author":"B Klein","year":"1989","unstructured":"Klein B, Zhang XG, Jourdan M et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989; 73: 517\u2013526.","journal-title":"Blood"},{"key":"BF1705138_CR16","first-page":"193","volume":"1","author":"B Klein","year":"1990","unstructured":"Klein B, Zhang XG, Jourdan M et al. Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma. Eur Cytokine Netw 1990; 1: 193\u2013201.","journal-title":"Eur Cytokine Netw"},{"key":"BF1705138_CR17","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1182\/blood.V83.12.3654.3654","volume":"83","author":"XG Zhang","year":"1994","unstructured":"Zhang XG, Gaillard JP, Robillard N et al. Reproducible obtaining myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 1994; 83: 3654\u20133663.","journal-title":"Blood"},{"key":"BF1705138_CR18","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1002\/eji.1830210727","volume":"21","author":"M Portier","year":"1991","unstructured":"Portier M, Rajzbaum G, Zhang XG et al. In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma. Eur J Immunol 1991; 21: 1759\u20131762.","journal-title":"Eur J Immunol"},{"key":"BF1705138_CR19","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1182\/blood.V91.7.2501","volume":"91","author":"P Greipp","year":"1998","unstructured":"Greipp P, Leong T, Benett JM et al. Plasmablastic morphology, an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E 9486 report by the ECOG Myeloma Laboratory Group. Blood 1998; 91: 2501\u20132507.","journal-title":"Blood"},{"key":"BF1705138_CR20","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1002\/(SICI)1097-0142(19980515)82:10<1860::AID-CNCR7>3.0.CO;2-R","volume":"82","author":"R Stasi","year":"1998","unstructured":"Stasi R, Brunetti M, Parma A et al. The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma. Cancer 1998; 82: 1860\u20131866.","journal-title":"Cancer"},{"key":"BF1705138_CR21","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1182\/blood.V78.5.1198.1198","volume":"78","author":"B Klein","year":"1991","unstructured":"Klein B, Widjenes J, Zhang XG et al. Murine anti-IL-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 1991; 78: 1198\u20131204.","journal-title":"Blood"},{"key":"BF1705138_CR22","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1182\/blood.V86.2.685.bloodjournal862685","volume":"86","author":"R Bataille","year":"1995","unstructured":"Bataille R, Barlogie B, Lu ZY et al. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 1995; 86: 685\u2013691.","journal-title":"Blood"},{"key":"BF1705138_CR23","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S1043-4666(05)80007-9","volume":"5","author":"ZY Lu","year":"1993","unstructured":"Lu ZY, Brailly H, Rossi JF et al. Overall interleukin-6 production exceeds 7\u2009mg\/day in multiple myeloma complicated by sepsis. Cytokine 1993; 5: 578\u2013582.","journal-title":"Cytokine"},{"key":"BF1705138_CR24","first-page":"3124","volume":"86","author":"ZY Lu","year":"1995","unstructured":"Lu ZY, Brailly H, Wijdenes J et al. Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments. Blood 1995; 86: 3124\u20133131.","journal-title":"Blood"},{"key":"BF1705138_CR25","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/(SICI)1097-0215(19970729)72:3<424::AID-IJC9>3.0.CO;2-R","volume":"72","author":"JY Blay","year":"1997","unstructured":"Blay JY, Rossi JF, Widjenes J, Menetrier-Caux C . Role of interleukin-6 in the paraneoplastic syndrome associated with renal cell carcinoma. Int J Cancer 1997; 72: 424\u2013430.","journal-title":"Int J Cancer"},{"key":"BF1705138_CR26","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1182\/blood.V97.2.483","volume":"97","author":"MA Frassanito","year":"2001","unstructured":"Frassanito MA, Cussmai A, Iodice G, Dammacco F . Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis. Blood 2001; 97: 483\u2013489.","journal-title":"Blood"},{"key":"BF1705138_CR27","first-page":"4633","volume":"55","author":"N Borsellino","year":"1995","unstructured":"Borsellino N, Belldegrun A, Bonavida B . Endogenous interleukin-6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res 1995; 55: 4633\u20134639.","journal-title":"Cancer Res"},{"key":"BF1705138_CR28","first-page":"590","volume":"55","author":"Y Mizutani","year":"1995","unstructured":"Mizutani Y, Bonavida B, Koishihara Y et al. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res 1995; 55: 590\u2013596.","journal-title":"Cancer Res"},{"key":"BF1705138_CR29","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/0167-5699(95)80161-8","volume":"16","author":"B Klein","year":"1995","unstructured":"Klein B, Brailly H . Cytokine-binding proteins: stimulating antagonists. Immunol Today 1995; 16: 216\u2013220.","journal-title":"Immunol Today"},{"key":"BF1705138_CR30","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1182\/blood.V85.4.917.bloodjournal854917","volume":"85","author":"F Montero-Julian","year":"1995","unstructured":"Montero-Julian F, Klein B, Gautherot E, Brailly H . Pharmacokinetic study of anti-interleukin-6 (IL-6) therapy with monoclonal antibodies: enhancement of IL-6 clearance by cocktails of anti-IL-6 antibodies. Blood 1995; 85: 917\u2013924.","journal-title":"Blood"},{"key":"BF1705138_CR31","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","volume":"102","author":"J Blade","year":"1998","unstructured":"Blade J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated with high-dose therapy and haematopoietic stem cell transplantation. Myeloma subcommittee of the EBMT. European bone Marrow Transplant. Br J Haematol 1998; 102: 1115\u20131123.","journal-title":"Br J Haematol"},{"key":"BF1705138_CR32","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/0161-5890(91)90004-4","volume":"28","author":"J Widjenes","year":"1991","unstructured":"Widjenes J, Clement C, Klein B et al. Human recombinant dimeric IL-6 binds to its receptor as detected by anti-IL-6 monoclonal antibodies. Mol Immunol 1991; 28: 1183\u20131192.","journal-title":"Mol Immunol"},{"key":"BF1705138_CR33","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P . Non parametric estimations from incomplete observations. J Am Stat Assoc 1958; 53: 457.","journal-title":"J Am Stat Assoc"},{"key":"BF1705138_CR34","first-page":"301","volume":"18","author":"M Steffen","year":"1996","unstructured":"Steffen M, Durken M, Pichlmeier U et al. Serum interleukin-6 levels during bone marrow transplantation: impact on transplant-related toxicity and engraftment. Bone Marrow Transplant 1996; 18: 301\u2013307.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705138_CR35","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1200\/JCO.1995.13.10.2585","volume":"13","author":"GJ Veldhuis","year":"1995","unstructured":"Veldhuis GJ, Willemse PH, Sleijfer DT et al. Toxicity and efficacy of escalating dosages of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non-small-cell lung cancer. J Clin Oncol 1995; 13: 2585\u20132593.","journal-title":"J Clin Oncol"},{"key":"BF1705138_CR36","first-page":"4653","volume":"9","author":"M Trickha","year":"2003","unstructured":"Trickha M, Corringham R, Klein B, Rossi JF . Targetted anti-interleukin-6 monoclonal antibody therapy for cancer: review of the rationale and clinical evidence. Clin Cancer Res 2003; 9: 4653\u20134665.","journal-title":"Clin Cancer Res"},{"key":"BF1705138_CR37","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1056\/NEJM199403033300904","volume":"330","author":"JT Beck","year":"1994","unstructured":"Beck JT, Hsu SM, Wijdenes J et al. Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 1994; 330: 602\u2013605.","journal-title":"N Engl J Med"},{"key":"BF1705138_CR38","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1182\/blood.V84.8.2472.2472","volume":"84","author":"D Emilie","year":"1994","unstructured":"Emilie D, Widjenes J, Gisselbrecht C et al. Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: effects on lymphoma growth and on B clinical symptoms. Blood 1994; 84: 2472\u20132479.","journal-title":"Blood"},{"key":"BF1705138_CR39","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1365-2249.1994.tb06145.x","volume":"98","author":"E Legouffe","year":"1994","unstructured":"Legouffe E, Liautard J, Gaillard JP et al. Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6. Clin Exp Immunol 1994; 98: 323\u2013329.","journal-title":"Clin Exp Immunol"},{"key":"BF1705138_CR40","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1002\/hep.1840120517","volume":"12","author":"JV Castell","year":"1990","unstructured":"Castell JV, Gomez-Lechon MJ, David M et al. Acute phase response of human hepatocytes: regulation of acute phase protein synthesis by interleukin-6. Hepatology 1990; 12: 1179\u20131186.","journal-title":"Hepatology"},{"key":"BF1705138_CR41","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1182\/blood.V94.3.923.415k08_923_931","volume":"94","author":"O Kollet","year":"1999","unstructured":"Kollet O, Aviram R, Chebath J . The soluble interleukin-6 (IL-6) receptor\/IL-6 fusion protein enhances in vitro maintenance and proliferation of human CD34+CD38-\/low cells capable of repopulating severe combined immunodeficiency mice. Blood 1999; 94: 923\u2013931.","journal-title":"Blood"},{"key":"BF1705138_CR42","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s002770100345","volume":"80","author":"L Sun","year":"2001","unstructured":"Sun L, Liu X, Qiu L et al. Administration of plasmid DNA expressing human interleukin-6 significantly improves thrombocytopoiesis in irradiated mice. Ann Hematol 2001; 80: 567\u2013572.","journal-title":"Ann Hematol"},{"key":"BF1705138_CR43","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1182\/blood.V98.9.2720","volume":"98","author":"A Kaser","year":"2001","unstructured":"Kaser A, Brandacher G, Steurer W et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood 2001; 98: 2720\u20132725.","journal-title":"Blood"},{"key":"BF1705138_CR44","first-page":"231","volume":"22","author":"T Efferth","year":"2002","unstructured":"Efferth T, Fabry U, Osieka R . Interleukin-6 affects melphalan-induced DNA damage and repair in human multiple myeloma cells. Anticancer Res 2002; 22: 231\u2013234.","journal-title":"Anticancer Res"},{"key":"BF1705138_CR45","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1182\/blood.V96.9.3175","volume":"96","author":"M Rowley","year":"2000","unstructured":"Rowley M, Liu P, Van Ness B . Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin-6, dexamethasone, doxorubicin and melphalan. Blood 2000; 96: 3175\u20133180.","journal-title":"Blood"},{"key":"BF1705138_CR46","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/sj.bmt.1703272","volume":"28","author":"EM Tegg","year":"2001","unstructured":"Tegg EM, Griffiths AE, Lowenthal RM et al. Association between high interleukin-6 levels and adverse outcome after autologous haemopoietic stem cell transplantation. Bone Marrow Transplant 2001; 28: 929\u2013933.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705138_CR47","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/sj.bmt.1701763","volume":"23","author":"P Moreau","year":"1999","unstructured":"Moreau P, Milpied N, Mah\u00e9 B et al. 220\u2009mg\/m2 melphalan followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma. Bone Marrow Transplant 1999; 23: 1003\u20131006.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705138_CR48","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","volume":"36","author":"BGM Durie","year":"1975","unstructured":"Durie BGM, Salmon SE . A critical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842\u2013854.","journal-title":"Cancer"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1705138","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1705138.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1705138.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:29:24Z","timestamp":1648081764000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1705138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,22]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2005,11,1]]}},"alternative-id":["BF1705138"],"URL":"https:\/\/doi.org\/10.1038\/sj.bmt.1705138","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8,22]]},"assertion":[{"value":"18 February 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2005","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2005","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}